Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Cpcsea ppt
1. CPCSEA Guidelines
A Seminar presented as a part of
I Year M. Pharm I semester Requirement
ACY 2019 – 20
By
M. Kavya Nainita
Regd. No. 19L81S0406
Pharmaceutical Quality Assurance,
Raghavendra Institute of Pharmaceutical
Education & Research (AUTONOMOUS),
Anantapuramu.
18-04-2020 1
3. Introduction
• Committee for the Purpose of Control and
Supervision of Experiments on Animals.
• It is statutory committee.
• Established under Section 15 of the prevention
of cruelty to animals act 1960.
• Committee was reconstituted on 17 February,
2016.
18-04-2020 3
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
4. CPCSEA
Definition
Committee for the purpose of control and
supervision of experiments on animals.
• It is statutory body formed by the act of the Indian
Parliament under the Prevention of Cruelty to
Animals Act, 1960.
• The secretariat of CPCSEA has published its
guidelines, to ensure humane and ethical treatment of
animals, while carrying out legitimate scientific
research.
• It was formed in 1964.
• Headquarters is at Ballabhgarh of Faridabad district
in Haryana.
18-04-2020 4
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
5. GOAL
• To promote the humane care of animals used in
research.
• To provide specifications that will enhance animals
well being and quality of research.
• Effective functioning of IAEC.
• To provide guideline for:
Housing, care, breeding and maintenance.
Source of experimental animals
Acceptable experimental procedures for
anaesthesia and euthanasia.
OBJECTIVE
18-04-2020 5
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
6. COMMITTEE MEMBERS
• It is composed of
Members of the scientific
community
Regulatory authorities
Animal activists
The committee has 20 Experts
and 3 Official Members.
18-04-2020 6
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
7. 1 Special Secretary / Additional Secretary, In-
charge of Animal Welfare, Government of
India, Ministry of Environment, Forest &
Climate Change, New Delhi
Chairman
2 Joint Secretary (Animal Welfare), Ministry
of Environment, Forest & Climate Change,
New Delhi
Vice Chairman
3 Representative from Drug Controller
General of India (DCGI), New Delhi
Member
4 Representative from Medical Council of
India (MCI), New Delhi
Member
5 Representative from Veterinary Council of
India (VCI), New Delhi
Member
18-04-2020 7
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
8. 6 Representative from Pharmacy
Council of India (PCI), New Delhi
Member
7 Representative from University Grants
Commission (UGC), New Delhi
Member
8 Representative from Animal Welfare
Board of India (AWBI), Ballabhgarh
Member
9 Dr. Suresh Pothani, Representative
ICMR, Director In Charge & Scientist
“G” ICMR – National Animal
Resource Facility for Biomedical
Research, Hyderabad
Member
10 Prof. Asmita Gajbhiye, Professor &
Head, Dept of Pharmaceutical
Sciences, Dr. H.S. Gour
Vishwavidyalaya, Sagar
Member
18-04-2020 8
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
9. 11 Prof. Alok Dhawan, Director, CSIR –
Indian Institute of Toxicology
Research, Lucknow
Member
12 Dr. Anurag Agrawal, Director, CSIR
– Institute of Genomics & Integrative
Biology, New Delhi
Member
13 Dr. Ram Vishwakarma, Director,
CSIR – Indian Institute of Integrative
Medicine, Jammu
Member
14 Dr. Pardeep Kumar Yadav, Senior
Veterinary Officer, All India Institute
of Medical Science, New Delhi
Member
15 Dr. S.G. Ramachandra, Chief
Research Scientist, Central Animal
Facility, Indian Institute of Science,
Bangalore
Member
18-04-2020 9
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
10. 16 Dr. Subeer S. Majumdar, Director,
National Institute of Animal
Biotechnology, Hyderabad
Member
17 Prof. Dr. M. Ramachandra Mohan,
Professor, Dept of Zoology, Bangalore
University
Member
18 Prof. Madan Mohan Chaturvedi,
Professor and Head, Department of
Zoology, University of Delhi, New Delhi
Member
19 Prof. Aditya Kumar, Director, SKS
Institute, Mathura
Member
20 Director/Deputy Secretary (Animal
Welfare) Ministry of Environment,
Forests & Climate Change, New Delhi.
Member
18-04-2020 10
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
11. Forms
Forms Purpose
FORM A [As per rule 5(a)] Application for Registration
with CPCSEA
Form B (per rule 8(a) Submission of Research
Protocol (s) on Large Animals
Form C Record of Animals bred /
acquired
Form D Record of Animals Acquired
and Experiments performed
FORM- E Record of animals sold
18-04-2020 11
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
12. IAEC
• Institutional animal ethical committee.
Definition:
• Body comprising of a group of persons
recognized and registered by the CPCSA.
Function:
• Review and approve all types of protocols for
research involving animal experimentation.
• Obtain the periodic reports on research
development and shall ensure visit to animal
house facility and laboratory.
18-04-2020 12
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
14. • Role of CPCSEA is to monitor animal.
Experiments through ethics committees set up
in institutions (IAEC).
• IAEC scrutinize all project proposals for
experimentation on animals.
For small animals- give the final
approval
For large animals-make its
recommendation to SCL
(Sub-Committee on Large
Animals)
18-04-2020 14
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
15. Qualification
• B. V. Sc
• M.Sc. (Zoology/ Animal Sciences/ Animal
Biotechnology)
• M.Sc. / MTech (Life Sciences, Biological
Sciences/ Biochemistry/ Biotechnology/
Biomedical Engineering) with experience in
animal handling and animal research.
• M. Pharm with experience in animal handling
and animal research.
• MD/ MS with research experience in laboratory
animal handling.
18-04-2020 15
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
16. • Age limit: 65 years.
• Duration: 5 years.
• Inspection report of animal house with
photographs by IAEC members is required to
be sent once in a calendar year.
• If action is required, the facility must provide
within 30 days.
18-04-2020 16
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
17. Veterinary care
•Adequate veterinary care must be provided and
is the responsibility of a veterinarian or a person
who has training or experience in laboratory
animal sciences and medicine.
•Observed regularly for sign of illness, injury or
abnormal behaviour.
•Contagious disease – isolated from healthy
animal.18-04-2020 17
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
18. Surveillance, Diagnosis, Treatment
and Control of disease
(Annexure 1 and 2)
• All animals should be observed for signs of
illness, injury or abnormal behaviour by
animal house staff.
• Unexpected deaths and signs of illness,
distress or other deviations from normal health
conditions in animals.
18-04-2020 18
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
19. Physical Relationship of Animal
Facilities to Laboratories
(Annexure-3)
• Separation of animal facilities from personnel
areas such as offices, conference rooms, and
other laboratories.
• Located away from dust, smoke, noise, wild
rodents, insects and birds.
• Animal rooms should occupy 50-60% of
constructed area.
18-04-2020 19
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
20. Transport of laboratory animals (Annexure – 4)
Mouse Rat Hamster Guinea
pig
Rabbit Cat Dog Monkey
Max.no
Of
animals/
cage
25 25 25 12 2 1 or 2 1 or 2 1
Material
used in
transport
box
Metal
cardboard,
synthetic
material
metal metal Bamboo/
wood/metal
Space/
animal
(cm²)
Minimum
height of
box (cm)
20-25
12
80-
100
14
80-100
12
160-180
15
1000-
1200
30
1400-
1500
40
3000
50
2000-4000
48
18-04-2020 20
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
22. Anaesthesia
(Annexure-5)
• Sedatives, analgesics, anaesthetics should be used to
control pain or distress under experiment.
• Before using anaesthetics the animal is prepared for
anaesthesia by overnight fasting and using pre-
anaesthetics (scopolamine, atropine, diazepam, etc.)
• The animal should remain under veterinary care till it
completely recovers from anaesthesia and
postoperative stress.
Narcosis
Relaxation Analgesia18-04-2020 22
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
23. Euthanasia
(Annexure-6)
• Death without causing anxiety, pain or distress
with minimum time lag phase.
• Done when an animal required to be sacrificed
or termination of an experiment or otherwise
for ethical reasons.
• Tranquilizers have to be administered to larger
species such as monkeys, dogs and cats before
an euthanasia procedure.
18-04-2020 23
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
24. Animal care and Technical
Personnel
(Annexure-7)
• Animal care programs
• On-the-job training
• Trained person in laboratory animal science.
• Protective clothing (face masks, head covers,
aprons, gloves, gumboots, other footwear, etc.)
18-04-2020 24
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
25. Animal Experimentation Involving
Hazardous Agents
(Annexure-8)
• Policies governing experimentation with
hazardous agents.
• Examine the proposal on animal experiments
involving hazardous agents.
• IBSC members are knowledgeable about
hazardous agents are in place in most of the
higher-level education, research institutes and in
many pharmaceutical industries for taking care of
safety issues.
18-04-2020 25
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
26. Animal procurement
• All animals must be acquired lawfully as per
the CPCSEA guidelines.
• A health surveillance program for screening
incoming animals should be carried out to
assess animal quality.
• Each consignment of animals should be
inspected for compliance with procurement
specifications.
18-04-2020 26
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
27. Quarantine
Definition:
• Separation of newly received animals until the
health and possibly the microbial status of
newly received animal have been determine.
• An effective quarantine minimizes the chance
for introduction of pathogens into an
established colony.
• Quarantine period :
small lab animals- 1 week to 1 month.
large lab animal – 6weeks.
18-04-2020 27
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
28. Experimental area
• Experiments should be carried out in a
separate area away from the place where they
are housed.
• Separate functional areas for:
surgical support
Treatment of animals
Post operative and
intensive care
18-04-2020 28
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
29. Stabilization and Separation
• Physiologic, psychological and nutritional
stabilization should be given before their use.
• Separation is needed to prevent interspecies
diseases transmission and to eliminate anxiety
and possible physiological and behavioural
changes due to interspecies conflict.
• To prevent anxiety and behavioural changes.
18-04-2020 29
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
30. Physical facilities
Building materials Durable, moisture – proof, fire
resistant and pest resistant.
corridors Movement of personnel and equipment
Animal room doors Fit properly, no rust
Exterior windows Not recommended
floors Smooth, moisture proof, non absorbent,
skid proof floors
drains Proper drainage, floors should be sloped
Storage areas For feed, bedding, cages
Temperature and humidity Between 18-29 °C and 30-70 %
ventilation Designed with 12-15 air cycles / hour
Power and lighting Fluorescent lights
noise control Noise free environment
Concrete walls are more effective.
18-04-2020 30
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
31. Animal husbandry
Housing system:
Freedom of movement, normal
postural adjustments.
Comfortable environment
Easy access to food and water
Adequate ventilation
18-04-2020 31
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
32. Food and water
Feed should contain Feed should not contain
Moisture Insecticides, hormones, antibiotics,
fumigants or toxicants
Crude fibre, protein, fat Heavy metals
Essential bits, minerals, carbohydrates
•Palatable
•Non-contaminated
•Nutritionally adequate
•Fresh
•Uncontaminated drinking water
18-04-2020 32
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
33. Bedding
• Adsorbent, free from toxic chemicals.
• Should be removed and replaced periodically
with fresh materials.
• Ideal to change the bedding twice in a week.
• Newly delivered pups should be provided
wherever needed. (paper, cotton, etc.)
18-04-2020 33
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
34. Transgenic animals
• Transgenic animals are those animals, into
whose germs line foreign genes have been
engineered.
Used for study of biological functions of
specific genes.
• Knockout animals are those specific genes
have been disrupted leading to loss of function.
Maintained in clean room environment or in
animal isolators.
18-04-2020 34
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
35. Waste disposal
• Removed regularly and frequently.
• Disposed in a safe and sanitary manner.
• Preferred method – Incineration (thermal
treatment – waste materials converts waste into
ash, flue gas and heat).
• Waste cans containing animal tissue, carcasses
and hazardous wastes – leak proof.
• Cold storage might be necessary to prevent
decomposition of biological wastes.
18-04-2020 35
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
36. Emergency, Weekend And Holiday
Care
• If any emergency, institutional security
personnel and fire or police officials should be
able to reach responsible persons for the
animals.
• Emergency veterinary care.
• Posting emergency procedures, names, or
telephone numbers in animals facilities in
security department.
18-04-2020 36
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
37. Multiple surgical procedures on
single animal
• No animal should be used for experimentation
for more than 3 years unless adequate
justification is provided.
18-04-2020 37
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
38. Breeding and Genetics
• The breeding stock must be procured from
CPCSEA registered breeders or suppliers
ensuring that genetic makeup and health status
of animal is known.
18-04-2020 38
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
39. Record keeping
• Staff record- both technical and non-technical.
• Health record of staff animals.
• All SOP’s relevant to the animals.
• Breeding, stock, purchase and sales records.
• Records of experiments conducted with the
number of animals used.
• Death record
• Clinical record of sick animals.
• Training record of sick animals
• Training record of staff involved.
18-04-2020 39
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
40. Standard operating procedures
• Name of author
• Title of sop
• Date of preparation
• Reference of previous SOP
• Objectives
• Detailed information of instruments used in
animal methodology.(Model no., Serial no.)
• Normal value of all parameters
• Hazard identification and risk assessment.
18-04-2020 40
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
41. References
• CPCSEA.nic.in
• Appendix I of the New Zealand “Good Practice
Guide for the Use of Animals in Research, Testing
and Teaching” entitled “Pain: Some Concepts and
Definitions”.
• Derelanko MJ. The toxicologist's pocket
handbook. CRC Press; 2017 Nov 6.
• Olfert ED, Cross BM, McWilliam AA, editors.
Guide to the care and use of experimental
animals. Ottawa: Canadian Council on Animal
Care; 1993.
18-04-2020 41
PHARMACEUTICAL QUALITY ASSURANCE
RIPER
42. I'm so proud !
All of my kids
are going into
research.
18-04-2020 42
PHARMACEUTICAL QUALITY ASSURANCE
RIPER